Cambridge Healthtech Institute’s 4th Annual

Targeting NASH

Drug Development for the Fatty and Fibrotic Liver

September 16-17, 2020

 

Non-alcoholic steatohepatitis (NASH) is a disease of the liver that starts with a build-up of fat in the organ and if inflammation is also present, results in fibrosis and disfunction of the liver which can sometimes lead to cirrhosis, a type of liver cancer. No medical treatments for NASH yet exist, but drug discovery efforts against the disease are growing. There are a few drug candidates progressing in clinical trials, but there have also been a few recent failures. CHI’s Targeting NASH conference convenes leading drug discovery and development researchers and industry experts to share the latest results and discuss important questions in the field, such as which target classes still have potential, what are promising drug combinations, and best practices for clinical trial design.

At Discovery on Target, this NASH conference will be followed by a 1.5-day conference on the related topic of Fibrosis.

Who should attend: Heads of R&D, Principal Scientists, Discovery Scientists, Pharmacologists, Professors, Post-Doctoral Fellows, Graduate Students in Departments such as: Immunology, Inflammation, Metabolism, Liver Disease, Fibrosis, Diabetes.

 

Coverage will include, but is not limited to:                                        

  • Clinical-stage compounds and their targets (FXR, PPAR, THR-b, FGF21, Galectin)
  • New NASH molecular targets
  • Biomarkers
  • New types of cellular models (3D, stem cell)
  • Clinical trial design strategies
  • Relevant clinical endpoints
  • NASH in the context of cirrhosis

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is February 26, 2020.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Email: reymael@healthtech.com